0001607062-23-000365.txt : 20230714 0001607062-23-000365.hdr.sgml : 20230714 20230714132430 ACCESSION NUMBER: 0001607062-23-000365 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230713 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230714 DATE AS OF CHANGE: 20230714 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Healthcare Triangle, Inc. CENTRAL INDEX KEY: 0001839285 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373] IRS NUMBER: 843559776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40903 FILM NUMBER: 231088674 BUSINESS ADDRESS: STREET 1: 4309 HACIENDA DR. STREET 2: SUITE 150 CITY: PLEASANTON STATE: CA ZIP: 945888 BUSINESS PHONE: 925-270-4812 MAIL ADDRESS: STREET 1: 4309 HACIENDA DR. STREET 2: SUITE 150 CITY: PLEASANTON STATE: CA ZIP: 945888 8-K 1 hcti071423form8k.htm 8-K
0001839285 false 0001839285 2023-07-13 2023-07-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) July 13, 2023

 

HEALTHCARE TRIANGLE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40903   84-3559776
(State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)

 

 

7901 Stoneridge Dr., Suite 220 Pleasanton, CA 94588

(Address of principal executive offices)

 

(925)-270-4812

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class   Trading Symbol(s)   Name of each exchange
on which registered
Common Stock, par value $0.00001 per share   HCTI   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 1 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 13, 2023, Healthcare Triangle Inc. (the “Company”) entered into a revised board agreement with Mr. Dave Rosa, Chairman of the Board of Directors of the Company (the “Agreement”), effective July 1, 2023. Mr. Rosa qualifies as an ‘independent director’ for purposes of the NASDAQ listing standards, and apart from being the Chairman of the Board, serves as Chairman of the Compensation Committee and as a member on the Company’s Audit Committee.

Mr. Rosa has served as a member of our board of directors since August 2021. Since 2016, Mr. Rosa has been and currently is President and CEO of NeuroOne Medical Technologies (NMTC: Nasdaq), a publicly traded company on the Nasdaq. He also serves on the boards of Biotricity (BTCY: OTC), a publicly traded company on the Over the Counter (OTC) platform, where he currently serves as compensation committee chairman and Neuro Event Labs, a privately held company in Finland, where he currently serves as Chairman of the Board. Mr. Rosa has over 25 years of experience holding a variety of senior management roles representing several medical device markets. His recent experience includes developing early-stage companies to commercialization and Nasdaq listing. Mr. Rosa holds a Master of Business Administration degree from Duquesne University and Bachelor of Science degree in Commerce and Engineering from Drexel University.

Per the revised Agreement, Mr. Rosa will receive compensation consistent with his expanded duties and critical service to the Company. Mr. Rosa’s compensation, per the Agreement Mr. Rosa shall comprise of (i) an annual cash stipend of $120,000, and (b) an annual grant of stock options for 10,000 shares of the Company’s common stock under its 2020 Stock Incentive Plan.

Among his key responsibilities as Chairman of the Board, Mr. Rosa will ensure compliance with corporate governance standards applicable to the Company, chair meetings of the Company’s Board, shareholders and executive sessions of the Board, coordinate the activities of the directors of the Board, serve as a formal liaison between the Company’s senior management and the directors of the Board, coordinate the activities of the Board’s operating committees and assist management in maintaining effective communication with the Company’s shareholders. The Agreement may be terminated by Mr. Rosa immediately by notice in writing.

There are no family relationships between Mr. Rosa and any of the Company’s directors or executive officers and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

The above description is a summary of the Agreement and does not purport to be complete and is subject to, and is qualified in its entirety by reference to, the full text of the Agreement, which is filed as Exhibit 10.1, respectively, with this Current Report on Form 8-K and are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number Description
10.1 Board Agreement, dated as of July 13, 2023, by and between the Company and Dave Rosa.

 2 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  Healthcare Triangle, Inc.
   
Date: July 14, 2023 By: /s/ Thyagarajan Ramachandran
  Name: Thyagarajan Ramachandran
  Title: Chief Financial Officer

 

 3 

 

 

EX-10.1 2 ex10_1.htm EXHIBIT 10.1

 

Dave Rosa

9705 Emerson Court

Eden Prairie, MN 55347

 

July 13, 2023

 

RE: Healthcare Triangle, Inc.’s Board of Directors - Board Agreement

 

Dear Dave:

The Compensation Committee and the Board of Directors (the “Board”) of Healthcare Triangle, Inc. (the “Company”) has unanimously consented to revise the Board fees effective July 01, 2023.

1. Your Duties:

a)  You will be expected to attend (either in person or by teleconference) all regular meetings of the Board, of which we expect to hold approximately four to six per annum, as well as to attend (either in person or by teleconference), if feasible, any special meetings of the Board and to sign all written consents if you deem appropriate. In addition, you will be expected to perform such other duties as are reasonably contemplated by your holding office as a director of the Company or which may reasonably be assigned to you by the Board from time to time, including Committee(s) membership.

b)  As a director you will at all times act as a fiduciary in the service of the best interests of the Company. In addition, you agree to (i) provide all information regarding yourself as the Company requires to satisfy its disclosure obligations under applicable securities laws; and (ii) timely file with the Securities and Exchange Commission all reports and schedules required of you in your personal capacity by virtue of your relationship with the Company (e.g., Forms 3, 4 and 5 as contemplated by Section 16(a) of the Securities Exchange Act of 1934).

c)  As you will appreciate, your time commitment will ultimately be a function of the matters confronting the Company from time to time and matters properly requiring your attention as a director of the Company.

d)  You shall comply with all the fiduciary-duty obligations of a director as imposed by Delaware law. Subject to your fiduciary-duty obligations as a director as imposed by Delaware law, this Letter does not otherwise restrict you from accepting appointment as a director of any other company, providing consulting services, becoming employed by or engaging in any other business or other activity whatsoever.

2. Remuneration:

a)  Cash: You will receive an annual cash stipend of $120,000. Cash stipend of $40,000 for being a Board member, $60,000 for being the Chairman of the Board and $20,000 for being Chairman of the Compensation Committee, payable on the first day of each calendar quarter, for your service on the Board.

b)  Annual Options: The Company expects to provide you for service on the Board, an annual grant of stock options for 10,000 shares of the Company’s common stock on the date of grant under our 2020 Stock Incentive Plan (Plan). Such stock options shall remain exercisable until the earlier of the 5 years from the date of grant or 18 months after the cessation of service, whichever is sooner.

c)  Expenses: Subject to you providing the Company with receipts or other evidence of payment, the Company will pay for or reimburse you for all travelling, hotel and other expenses reasonably incurred by you in connection with attending and returning from Board or Committee meetings or otherwise in connection with the Company's business. “Reasonable” air travel expenses assume economy class for flights under 4 hours and business class for flights over 4 hours.

3. Termination of Director Status:

a)  Your status as a director may be terminated at any time by the vote of the stockholders of the Company (including any failure to elect you for an ensuing term at any annual meeting of stockholders) in accordance with the certificate of incorporation and bylaws of the Company. Any such termination will not affect your rights under options that have become vested, subject to the post-service exercisability period.

b)  You acknowledge and agree that if the stockholders of the Company terminate your status as a Director (including any failure to elect you for an ensuing term at any annual meeting of stockholders), you will have no claim of any kind against the Company by reason of the termination.

c)  You are at liberty to resign from the Board at any time by notice in writing to the Company.

4. What happens after termination of Director Status?

If your Director status is terminated for any reason or you resign for any reason:

a)  The Company may set off any amounts you owe the Company against any amounts the Company owes to you as a Director at the date of termination except for amounts the Company is not entitled by law to set off;

b)  You must return all the Company's property (including property leased by the Company) to the Company on termination including all written or machine-readable material, software, computers, credit cards, keys and vehicles; and

c)  You shall return to the Company all confidential information and documentation (including any copies thereof) regarding the Company and its affiliates (including confidential information of third parties entrusted to the Company) within 5 business days following the Company's request and to delete or destroy any electronic or written information relating to the Company, as shall be requested by the Company.

5. Confidential Information:

a)  You acknowledge and agree that during your service with the Company, you will receive confidential information regarding the Company and its affiliates (including confidential information of third parties entrusted to the Company) and that you will not disclose any such information to any other party nor use for your own benefit or for the benefit of any third person any of the confidential information so obtained at any time during or after the term of your service with the Company without the Company's prior written consent.

b)  You recognize and affirm that in the event of your breach of any provision of this Section 5, monetary damages would be inadequate, and the Company and its subsidiaries would have no adequate remedy at law. Accordingly, you agree that in the event of a breach or threatened breach by you of the provisions of this Section 5, the Company, in addition and supplementary to any other rights and remedies existing in its favor, may apply to any court of law or equity of competent jurisdiction for specific performance and/or injunctive or other relief in order to enforce or prevent any violations of the provisions hereof (without posting a bond or other security).

6. Protection:

a)  During the term of your engagement hereunder, the Company will use reasonable commercial efforts to procure and maintain directors' and officers' liability insurance policies with a minimum of $5,000,000 Aggregate Limit, and to ensure that you are included as an insured thereunder.

b)  The Company will enter into a standard and customary Indemnification Agreement with you on terms reasonably acceptable to you which will provide for (i) your indemnification by the Company to the fullest extent permitted by law for all acts and/or omissions directly and/or indirectly related to any services provided by you to the Company and (ii) the advancement of your expenses in the event any action and/or investigation is commenced regarding any acts and/or omissions directly and/or indirectly related to any services provided by you to the Company.

7. Miscellaneous

a) Alterations: This Letter cannot be amended except in a writing signed by each party.

b)  Entire Agreement: This Letter constitutes the entire agreement between the parties in connection with its subject matter and supersedes all previous agreements or understandings between the parties in connection with its subject matter.

c)  Further Action: Each party must do, at its own expense, everything reasonably necessary (including executing documents) to give full effect to the performance of his/its obligations under this Letter and the transactions contemplated by it.

d)  Waiver: A party does not waive a right, power, or remedy (or any other right, power or remedy) if it fails to exercise or delays in exercising the right, power or remedy. A single or partial exercise of a right, power or remedy does not prevent another or further exercise of that or another right, power or remedy. A waiver of a right, power or remedy must be in writing and signed by the party giving the waiver.

e)  Relationship: This Letter does not create a relationship of employment, agency, or partnership between the parties. Unless the Board adopts a specific resolution so providing, you do not have authority to bind the Company to any contract or commitment; and you agree not to purport to do so.

f)  Governing Law: This Letter shall be governed by and construed in accordance with the laws of Delaware (without giving effect to choose of law principles or rules thereof that would cause the application of the laws of any jurisdiction other than Delaware).

g)  Severability: Any provision of this Letter, which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective only to the extent of such prohibition or unenforceability without invalidating or affecting the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

h)  Counterparts: This Letter may be executed in counterparts. All executed counterparts constitute one document.

[REMAINING PAGE INTENTIONALLY LEFT BLANK]

[SIGNATURE PAGES BELOW]

 1 

 

 

Please sign and return the attached copy of this Letter to indicate that you have read, have understood and accept the terms of your appointment.

    Very truly yours,
     
    Healthcare Triangle, Inc.
     
     
    By:_______________________
    Name: Thyagarajan Ramachandran
    Title: Chief Financial Officer
     
Agreed to and accepted by:    
     
     
Dave Rosa    

 2 

 

 

EX-101.SCH 3 hcti-20230623.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 hcti-20230623_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 hcti-20230623_pre.xml XBRL PRESENTATION FILE GRAPHIC 6 image_001.jpg GRAPHIC begin 644 image_001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Jul. 13, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 13, 2023
Entity File Number 001-40903
Entity Registrant Name HEALTHCARE TRIANGLE, INC.
Entity Central Index Key 0001839285
Entity Tax Identification Number 84-3559776
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 7901 Stoneridge Dr.
Entity Address, City or Town  Suite 220 Pleasanton
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94588
City Area Code (925)
Local Phone Number 270-4812
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.00001 per share
Trading Symbol HCTI
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 hcti071423form8k_htm.xml IDEA: XBRL DOCUMENT 0001839285 2023-07-13 2023-07-13 iso4217:USD shares iso4217:USD shares 0001839285 false 8-K 2023-07-13 HEALTHCARE TRIANGLE, INC. DE 001-40903 84-3559776 7901 Stoneridge Dr.  Suite 220 Pleasanton CA 94588 (925) 270-4812 false false false false Common Stock, par value $0.00001 per share HCTI NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://healthcaretriangle.com/role/Cover Cover Cover 1 false false All Reports Book All Reports hcti071423form8k.htm ex10_1.htm hcti-20230623.xsd hcti-20230623_lab.xml hcti-20230623_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hcti071423form8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "hcti071423form8k.htm" ] }, "labelLink": { "local": [ "hcti-20230623_lab.xml" ] }, "presentationLink": { "local": [ "hcti-20230623_pre.xml" ] }, "schema": { "local": [ "hcti-20230623.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "HCTI", "nsuri": "http://healthcaretriangle.com/20230623", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "hcti071423form8k.htm", "contextRef": "From2023-07-13to2023-07-13", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://healthcaretriangle.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "hcti071423form8k.htm", "contextRef": "From2023-07-13to2023-07-13", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthcaretriangle.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001607062-23-000365-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001607062-23-000365-xbrl.zip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